Altamont Pharma Acquisition Corp. (ALTP)
| Market Cap | 125.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 12.50M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
Altamont Pharma Acquisition, a blank check company targeting the biopharma and medical technology sectors, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Altamont Pharma Acquisition Corp. has filed to go public with an IPO on the NASDAQ.
About ALTP
Altamont Pharma Acquisition is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors, which aligns with our management team’s experience in healthcare investing and dru... [Read more...]
| Industry Blank Checks / SPAC | IPO Date Pending |
| CEO Mark Pearson | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol ALTP |